Hetero announces approval and launch of Movfor (Molnupiravir 200 mg)
Press Releases (Hetero)
-
-
Hetero's Biosimilar version of Tocilizumab receives emergency use authorization from DCGI
-
Hetero announces interim clinical results from phase III clinical trials of Molnupiravir conducted in India
-
RDIF and Hetero agree to produce over 100 million doses of the Sputnik V vaccine in India
-
Hetero announces the launch of ‘Favivir’ (Favipiravir 200 mg) in India to treat mild to moderate Covid-19
-
Hetero announces the approval and launch of first generic ‘COVIFOR’ (Remdesivir) in India for the treatment of Covid-19
